Xpovio Dosage Guide: Understanding Selinexor for Cancer Treatment

Understanding the correct dosage of any medication, especially powerful cancer treatments like Xpovio (selinexor), is crucial for maximizing efficacy and minimizing side effects. This comprehensive guide will delve into Xpovio dosage, providing detailed information on how it works, its uses, specific dosing schedules for various conditions, potential adjustments, and important precautions. As always, this information is for educational purposes and should not replace the personalized medical advice from your healthcare provider.

What is Xpovio (Selinexor)?

Xpovio is the brand name for the drug selinexor, an oral medication used in the treatment of certain types of cancer. It belongs to a class of drugs known as Selective Inhibitors of Nuclear Export (SINE) compounds. Selinexor works by blocking XPO1 (exportin 1), a protein that plays a critical role in transporting tumor suppressor proteins and growth-regulating proteins from the nucleus of a cell to the cytoplasm. In many cancer cells, XPO1 is overactive, leading to the inappropriate export of these crucial proteins, which then allows cancer cells to grow and multiply unchecked.

By inhibiting XPO1, Xpovio forces tumor suppressor proteins to accumulate in the nucleus, where they can exert their anti-cancer effects, ultimately leading to programmed cell death (apoptosis) in cancer cells. This unique mechanism of action makes Xpovio an important treatment option for patients with advanced or refractory cancers who may have limited other options.

Approved Uses of Xpovio

• Multiple Myeloma: Xpovio is approved in combination with other agents (like bortezomib and dexamethasone, or dexamethasone alone) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.
• Diffuse Large B-cell Lymphoma (DLBCL): Xpovio is also approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

How Xpovio Works

Selinexor's mechanism is quite sophisticated. Cancer cells often exhibit an overexpression of XPO1, which acts as a nuclear export pump. This pump actively removes key proteins from the cell nucleus, including tumor suppressor proteins (TSPs) like p53, p21, and IkB. When these TSPs are removed from the nucleus, they cannot perform their essential functions of regulating cell growth, DNA repair, and initiating apoptosis (programmed cell death) in damaged cells.

Xpovio works by binding to and inhibiting XPO1. This inhibition traps the tumor suppressor proteins within the nucleus of the cancer cells. With these proteins confined to the nucleus, they can accumulate to sufficient levels to reactivate their anti-cancer pathways. This leads to:

• Cell Cycle Arrest: Preventing cancer cells from dividing and multiplying.
• Apoptosis Induction: Triggering the self-destruction of cancer cells.
• Reduced Inflammation: By affecting proteins involved in inflammatory pathways.

The specificity of Xpovio for cancer cells, which often have a higher reliance on XPO1 for survival compared to healthy cells, contributes to its therapeutic effect. However, like all potent cancer drugs, it can affect healthy cells, leading to side effects.

Xpovio Dosage: The Basics

The dosage of Xpovio is highly individualized and depends on several factors, including the specific cancer being treated, the patient's overall health, kidney and liver function, and how well the patient tolerates the medication. It is crucial to follow your doctor's instructions precisely and never adjust your dose without consulting them.

Xpovio is taken orally, typically with water, and can be taken with or without food. However, taking it with food may help reduce some gastrointestinal side effects. It is often administered on specific days of the week, with rest days in between, as part of a cycle.

General Considerations for Xpovio Dosage

• Oral Administration: Xpovio comes in tablet form.
• Hydration: Patients are often advised to maintain adequate hydration during treatment.
• Anti-emetics: Prophylactic anti-emetic medications (to prevent nausea and vomiting) are often prescribed, especially during the initial cycles of treatment, due to Xpovio's common gastrointestinal side effects.
• Supportive Care: Close monitoring of blood counts, electrolytes, and other vital signs is essential.

Dosage for Multiple Myeloma

Xpovio is used in different combinations for multiple myeloma, and the dosage varies accordingly.

1. In Combination with Bortezomib and Dexamethasone (XVd)

This regimen is for adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.

• Xpovio (Selinexor): 100 mg taken orally once weekly on Day 1 of each week.
• Bortezomib: 1.3 mg/m² administered subcutaneously once weekly on Day 1 of each week.
• Dexamethasone: 20 mg taken orally twice weekly on Day 1 and Day 2 of each week.

Treatment cycles are typically 4 weeks long. The Xpovio and bortezomib doses are given on the same day, followed by dexamethasone on that day and the next. This cycle is repeated as long as the patient benefits and tolerates the treatment.

2. In Combination with Dexamethasone (Xd)

This regimen is for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

• Xpovio (Selinexor): 80 mg taken orally twice weekly on Day 1 and Day 3 of each week.
• Dexamethasone: 20 mg taken orally twice weekly on Day 1 and Day 3 of each week.

Treatment cycles are typically 4 weeks long. Xpovio and dexamethasone are given on the same two days each week. This regimen is continued as long as the patient benefits and tolerates the treatment.

Dosage for Diffuse Large B-cell Lymphoma (DLBCL)

For adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy:

• Xpovio (Selinexor): 60 mg taken orally twice weekly on Day 1 and Day 3 of each week.

Treatment cycles are typically 4 weeks long. This regimen is continued as long as the patient benefits and tolerates the treatment.

Dosage Adjustments: When and Why

Dosage adjustments are a critical aspect of Xpovio treatment due to its potent nature and potential for side effects. Your doctor will closely monitor your blood counts, kidney and liver function, and overall health to determine if a dose adjustment is necessary. Never adjust your dose or stop taking Xpovio without consulting your healthcare provider.

Reasons for Dose Reduction or Interruption

Common reasons for dose adjustments include:

• Hematologic Toxicities: Low blood cell counts (thrombocytopenia, neutropenia, anemia).
• Gastrointestinal Toxicities: Severe nausea, vomiting, diarrhea, or significant weight loss.
• Fatigue: Severe or debilitating fatigue.
• Hyponatremia: Low sodium levels.
• Other Severe Adverse Reactions: Any other serious or persistent side effects.

The specific guidelines for dose reduction or interruption are detailed in the prescribing information and will be managed by your oncologist based on the severity and persistence of the adverse event. For example, if a patient experiences severe thrombocytopenia, the doctor might temporarily hold Xpovio, restart at a lower dose (e.g., 80 mg once weekly or 60 mg twice weekly, depending on the initial regimen), or even discontinue the drug if the toxicity is unmanageable.

For Patients with Kidney or Liver Impairment

Xpovio is primarily metabolized in the liver and excreted via the kidneys. Therefore, patients with pre-existing kidney or liver impairment may require dose adjustments. Your doctor will assess your kidney and liver function before and during treatment and adjust the dose accordingly to prevent accumulation of the drug and increased toxicity.

• Renal Impairment: No initial dose adjustment is typically required for mild to moderate renal impairment. For severe renal impairment or end-stage renal disease, specific guidance should be sought from your doctor.
• Hepatic Impairment: No initial dose adjustment is typically required for mild hepatic impairment. For moderate or severe hepatic impairment, a dose reduction may be necessary.

How to Take Xpovio

Here are general guidelines for taking Xpovio:

• Take Orally: Swallow the tablets whole with water. Do not crush, chew, or break them.
• With or Without Food: Xpovio can be taken with or without food. Taking it with food may help reduce some gastrointestinal side effects like nausea.
• Consistent Schedule: Try to take your dose at the same time on the designated days to maintain consistent drug levels.
• Prophylactic Anti-emetics: Your doctor will likely prescribe anti-nausea medications (e.g., a 5-HT3 antagonist such as ondansetron, and/or a neurokinin-1 receptor antagonist such as aprepitant) to be taken before each Xpovio dose, especially during the first few cycles. Follow these instructions carefully.
• Hydration: Stay well-hydrated throughout your treatment.
• Do Not Handle Broken Tablets: If a tablet is broken, avoid direct contact with the skin or mucous membranes. If contact occurs, wash thoroughly with soap and water.

What to Do If You Miss a Dose

If you miss a dose of Xpovio, contact your doctor or pharmacist for advice. Do not take a double dose to make up for a missed dose. Your doctor will provide specific instructions based on your treatment schedule and how long it has been since the missed dose. Generally, if you remember within a certain timeframe, you might be advised to take it, but if it's too close to your next scheduled dose, you might be told to skip the missed dose and continue with your regular schedule.

What to Do in Case of Overdose

An overdose of Xpovio can lead to increased severity of side effects. If you suspect an overdose, seek immediate medical attention or call emergency services. Symptoms of overdose may include severe gastrointestinal issues, extreme fatigue, and profound hematologic toxicities.

Xpovio Side Effects

Like all medications, Xpovio can cause side effects. It's important to discuss any side effects you experience with your healthcare team, as many can be managed with supportive care or dose adjustments.

Common Side Effects (may affect more than 1 in 10 people)

• Gastrointestinal Issues: Nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain. These are very common and often managed with anti-emetics and anti-diarrheals.
• Fatigue: Mild to severe tiredness.
• Hematologic Abnormalities: Thrombocytopenia (low platelet count), neutropenia (low white blood cell count), anemia (low red blood cell count). These require regular blood monitoring.
• Weight Loss: Significant and unintentional weight loss.
• Hyponatremia: Low sodium levels in the blood.
• Infections: Due to lowered white blood cell counts.
• Other: Fever, shortness of breath, headache, dizziness, peripheral neuropathy.

Serious Side Effects (less common but require immediate medical attention)

• Severe Gastrointestinal Toxicity: Persistent severe nausea, vomiting, or diarrhea leading to dehydration and electrolyte imbalances.
• Severe Hematologic Toxicity: Profoundly low blood counts that can lead to serious infections or bleeding.
• Serious Infections: Pneumonia, sepsis, or other severe infections, especially in immunocompromised patients.
• Hyponatremia: Severe low sodium levels can lead to confusion, seizures, and coma.
• Fatigue: Debilitating fatigue that significantly impacts daily life.
• Neurological Toxicity: Dizziness, confusion, blurred vision, or other neurological symptoms.
• Cataracts: New or worsening cataracts have been reported.

Always inform your doctor about any new or worsening symptoms you experience.

Precautions and Warnings

Before starting Xpovio, and throughout your treatment, your doctor will consider several factors to ensure safe and effective use.

Before Taking Xpovio

• Medical History: Inform your doctor about all your medical conditions, especially kidney or liver problems, heart conditions, or any history of bleeding disorders or infections.
• Medications: Provide a complete list of all medications you are currently taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. This is crucial to check for potential drug interactions.
• Allergies: Inform your doctor if you have any known allergies to selinexor or any other medications.
• Pregnancy and Breastfeeding: Xpovio can cause harm to an unborn baby and is not recommended during pregnancy. Women of childbearing potential should use effective contraception during treatment and for at least 1 week after the last dose. Men with female partners of childbearing potential should use effective contraception during treatment and for at least 1 week after the last dose. It is not known if Xpovio passes into breast milk, so breastfeeding is not recommended during treatment and for 1 week after the last dose.

Drug Interactions

Xpovio can interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. Key interactions include:

• Strong CYP3A4 Inducers: These drugs (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) can decrease Xpovio levels, making it less effective. Co-administration should be avoided or managed with dose adjustments.
• Strong CYP3A4 Inhibitors: These drugs (e.g., ketoconazole, clarithromycin, ritonavir) can increase Xpovio levels, potentially increasing side effects. Dose adjustments or close monitoring may be necessary.
• P-glycoprotein (P-gp) Inhibitors/Inducers: Xpovio is a substrate of P-gp, so drugs affecting P-gp could alter Xpovio exposure.
• QT-prolonging agents: Caution is advised when co-administering Xpovio with drugs known to prolong the QT interval, as Xpovio itself can cause QT prolongation.

Always review your complete medication list with your oncologist and pharmacist.

Monitoring During Treatment

Regular monitoring is essential during Xpovio treatment. This includes:

• Complete Blood Counts (CBC): Weekly during the first two months, then as clinically indicated.
• Electrolyte Levels: Especially sodium, monitored regularly.
• Liver and Kidney Function Tests: Periodically throughout treatment.
• Weight: Monitored regularly due to potential for significant weight loss.
• Neurological Status: To monitor for any neurological toxicities.

When to See a Doctor

It is important to maintain open communication with your healthcare team throughout your Xpovio treatment. You should contact your doctor immediately if you experience any of the following:

• Severe or persistent nausea, vomiting, or diarrhea: Especially if it prevents you from eating or drinking.
• Signs of infection: Fever (temperature of 100.4°F or 38°C or higher), chills, sore throat, cough, burning with urination.
• Unusual bleeding or bruising: Including nosebleeds, bleeding gums, or petechiae (small red spots on the skin).
• Extreme fatigue or weakness: That is debilitating or significantly worsens.
• Symptoms of low sodium: Confusion, headache, dizziness, muscle weakness, seizures.
• Any new or worsening neurological symptoms: Such as blurred vision, difficulty concentrating, or changes in balance.
• Significant unintentional weight loss.
• Any other severe or bothersome side effects.

FAQs about Xpovio Dosage

Q1: Can I take Xpovio with food?

A1: Yes, Xpovio can be taken with or without food. Taking it with food may help reduce some gastrointestinal side effects like nausea.

Q2: What should I do if I forget to take a dose of Xpovio?

A2: If you miss a dose, contact your doctor or pharmacist right away for specific instructions. Do not take a double dose to make up for a missed dose.

Q3: Why is Xpovio dosage adjusted frequently?

A3: Xpovio is a potent medication, and dosage adjustments are often necessary to manage side effects, particularly gastrointestinal issues and blood count abnormalities, while maintaining treatment efficacy. Your doctor will carefully balance these factors.

Q4: How long will I need to take Xpovio?

A4: The duration of Xpovio treatment varies depending on your specific condition, how well you respond to the medication, and your tolerance of side effects. Treatment typically continues as long as you are benefiting from it and tolerating the side effects.

Q5: Is it safe to drink alcohol while on Xpovio?

A5: It's generally advisable to limit or avoid alcohol consumption during cancer treatment, as alcohol can exacerbate certain side effects (like nausea, fatigue) and may interact with medications. Discuss alcohol use with your doctor.

Q6: What is the most important thing to remember about Xpovio dosage?

A6: The most important thing is to always follow your doctor's instructions precisely and never alter your dose or treatment schedule without their explicit guidance. Regular communication with your healthcare team is vital for safe and effective treatment.

Conclusion

Xpovio (selinexor) represents an important therapeutic option for patients with certain advanced and refractory cancers like multiple myeloma and DLBCL. Understanding its dosage, administration, potential side effects, and necessary precautions is paramount for patients and caregivers. Due to its potent mechanism of action, Xpovio treatment requires close medical supervision, meticulous monitoring, and proactive management of adverse events. Always remember that this information serves as a general guide, and your specific treatment plan, including dosage, will be tailored by your oncologist to your individual needs and response to therapy. Consistent communication with your healthcare team is your best ally in navigating Xpovio treatment successfully.